Skip to main content

Advertisement

SpringerLink
Log in

Radioimmunoscintigraphy in patients with breast adenocarcinoma using technetium-99m labelled monoclonal antibody 170H.82: Report of a phase II study

  • Original Article
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Fifty-three women with clinical evidence of adenocarcinoma of the breast were studied with technetium-99m labelled monoclonal antibody (MAb) 170H.82 at protein doses of 1, 2 and 4 mg. An overall per lesion efficacy of 83.5% sensitivity and 97.7% positive predictive value was obtained. Efficacy appears higher in lesions restricted to the breast and local regional disease than systemic metastases. For the 2 mg dose the breast/local regional disease efficacy was 90% sensitivity and 90.2% positive predictive value. The biodistribution of this MAb was best represented by a two-compartment model with a distribution-phase half-life of 4.0±1.4 h, followed by an elimination-phase half-life of 39.6±6.6 h. In all six patients studied, the crticial organ was the kidney, with a mean radiation absorbed dose of 37±6.9 mGy/GBq. The accuracy of this imaging technique allows the development of diagnostic strategies for the routine use of the compound in patients with breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kelsey JL, Gammon MD. The epidemiology of breast cancer.CA Cancer J Clin 1991; 41: 146–165.

    PubMed  Google Scholar 

  2. Kopans DB.Breast imaging. Philadelphia: Lippincott, 1989.

    Google Scholar 

  3. Kopans DB. The positive predictive value of mammography.AJR 1992; 158: 521–526.

    PubMed  Google Scholar 

  4. Schmidt JG. The epidemiology of mass breast cancer screening — a plea for a valid measure of benefit.J Clin Epidemiol 1990; 43: 215–225.

    PubMed  Google Scholar 

  5. Lin PP, Allison DC, Wainstock J, et al. Impact of axillary lymph node dissection on the therapy patients.J Clin Oncol 1993; 11: 1536–1544.

    PubMed  Google Scholar 

  6. Rubin E. Critical pathways in the analysis of breast masses.RadioGraphics 1995; 15: 925–927.

    PubMed  Google Scholar 

  7. McEwan AJB, MacLean GD, Hopper HR, et al. MAb 170H.82: an evaluation of a novel panadenocarcinoma monoclonal antibody labelled with99mTc and with111In.Nucl Med Commun 1992; 13: 11–19.

    PubMed  Google Scholar 

  8. Longenecker BM, Willans DJ, MacLean GD, et al. Monoclonal antibodies and synthetic tumor associated glycoconjugates to study the expression of Thomsen-Friedenreich (TF)-like and Tn-like antigens on human cancers.J Natl Cancer Inst 1987; 78: 489–496.

    PubMed  Google Scholar 

  9. Samuel J, Noujaim AA, MacLean GD, et al. Analysis of human tumor associated Thomsen-Friedenreich antigen.Cancer Res 1990; 50: 4801–4808.

    PubMed  Google Scholar 

  10. Harris CC, Greer KL, Jaszczak RJ, et al. 99m-Te attenuation coefficients in water-filled phantoms determined with gamma cameras.Med Phys 1984; 11: 687.

    Google Scholar 

  11. Bailey DL, Hutton BF, Walker PJ. Improved SPECT using simultaneous emission and transmission tomography.J Nucl Med 1987; 28: 844.

    PubMed  Google Scholar 

  12. Ediss C, Tam YK. An interactive program for determining areas bounded by drug concentration curves using Lagrange interpolation.J Pharmacol Toxicol Methods 1995; 34: 165–168.

    PubMed  Google Scholar 

  13. Cloutier SR, Smith SA, Watson EE, et al. Dose to the fetus from radionuclides in the bladder.Health Phys 1973; 25: 147–161.

    PubMed  Google Scholar 

  14. Loevinger R, Budinger TF, Watson EE.MIRD primer for absorbed dose calculations. New York, NY: Society of Nuclear Medicine, 1988.

    Google Scholar 

  15. Xue LY, Noujaim AA, Sykes TR, et al. Role of transchelation in the uptake of Tc-99m antibodies in the liver and kidney.Q Nucl Med, in press.

  16. Lind P, Smola MG, Lechner P, et al. The immunoscintigraphic use of99mTc labelled monoclonal anti-CEA antibodies (BW 431/26) in patients with suspected primary recurrent metastatic breast cancer.Int J Cancer 1991; 47: 865–869.

    PubMed  Google Scholar 

  17. Kramer EL, DeNardo SJ, Liebes L, et al. Radioimmunolocalization of metastatic breast carcinoma using indium-111-methyl benzyl DTPA BrE-3 monoclonal antibody: phase I study.J Nucl Med 1993; 34: 1067–1074.

    PubMed  Google Scholar 

  18. Lamki LM, Buzdar AU, Singletary SE, et al. Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I study.J Nucl Med 1991; 32: 1326–1332.

    Google Scholar 

  19. Alexander C, Villena-Heinsen CE, Trampert L, et al. Radioimmunoscintigraphy of ovarian tumours with technetium-99m labelled monoclonal antibody-170: first clinical experiences.Eur J Nucl Med 1995; 22: 645–651.

    PubMed  Google Scholar 

  20. van Krooneburgh MJPG, Pauwels EJK. Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant disease.Nucl Med Commun 1988; 9: 919–930.

    PubMed  Google Scholar 

  21. Reynolds JC, del Vecchio S, Sakahara H, et al. Anti-murine antibody response to mouse monoclonal antibodies: clinical findings and implications.Nucl Med Biol 1989; 16: 121–125.

    Google Scholar 

  22. Janssen JAMJL, Blankestijn PJ, Docter R, et al. Effects of immunoscintigraphy with monoclonal antibodies in assays of hormones and tumor marker.Br Med J 1989; 298: 1511–1513.

    Google Scholar 

  23. Bischof Delaloye A, Delaloye B. Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion?Eur J Nucl Med 1995; 22: 571–580.

    PubMed  Google Scholar 

  24. Khalkhali I, Mena I, Jouanne E, et al. Prone scintimammography in patients with suspicion of carcinoma of the breast.J Am Coll Surg 1994; 178: 491–497.

    PubMed  Google Scholar 

  25. Kao CH, Wang SJ, Liu TJ. The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses.Eur J Nucl Med 1994; 21: 432–436.

    PubMed  Google Scholar 

  26. Lu G, Shih W-J, Huang H-Y, et al.99Tcm-MIBI mammoscintigraphy of breast masses: early and delayed imaging.Nucl Med Commun 1995; 16: 150–156.

    PubMed  Google Scholar 

  27. Burak Z, Argon M, Memis A, et al. Evaluation of palpable breast masses with Tc-99m MIBI: a comparative study with mammography and ultrasonography.Nucl Med Commun 1994; 15: 604–612.

    PubMed  Google Scholar 

  28. Lam WWW, Yang WT, Chan YL, et al. Detection of axillary lymph node metastases in breast carcinoma by technetium-99m sestamibi breast scintigraphy, ultrasound and conventional mammography.Eur J Nucl Med 1996; 23: 498–503.

    PubMed  Google Scholar 

  29. Adler DD, Wahl RL. New methods for imaging the breast: techniques, findings and potential.AJR 1995; 164: 19–30.

    PubMed  Google Scholar 

  30. Beany RP. Positron emission tomography in the study of human tumors.Semin Nucl Med 1984; 14: 324–341.

    PubMed  Google Scholar 

  31. Minn H, Soini I. [18F]Fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer.Eur J Nucl Med 1989; 15: 61–66.

    Article  PubMed  Google Scholar 

  32. Wahl RL, Cody R, Hutchins G, Mudgett E. Positron-emission tomography scanning of primary and metastatic breast carcinoma with the radiolabeled glucose analogue 2-deoxy[18F]fluoro-d-glucose.N Engl J Med 1991; 324: 200.

    Google Scholar 

  33. Nieweg OE, Kim EE, Wong W-H et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer.Cancer 1993; 71: 3920–3925.

    PubMed  Google Scholar 

  34. Institute for Clinical PET Breast Cancer Task Force. Positron emission tomography — clinical application and economic implications of PET in the assessment of axillary lymph node in volvement in breast cancer: a retrospective study.Abstract from the 1994 ICP Meeting

  35. Kotz D. Scintimammography: magic bullet or false promise?J Nucl Med 1995; 36: 15N-20N.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Alberta, Edmonton, Alberta, Canada

    S. A. McQuarrie, G. D. MacLean & A. J. B. McEwan

  2. Cross Cancer Institute, Edmonton, Alberta, Canada

    G. D. MacLean, K. Golberg & A. J. B. McEwan

  3. Biomira, Inc., Edmonton, Alberta, Canada

    G. D. MacLean & G. R. Boniface

Authors
  1. S. A. McQuarrie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. D. MacLean
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. R. Boniface
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Golberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. J. B. McEwan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

McQuarrie, S.A., MacLean, G.D., Boniface, G.R. et al. Radioimmunoscintigraphy in patients with breast adenocarcinoma using technetium-99m labelled monoclonal antibody 170H.82: Report of a phase II study. Eur J Nucl Med 24, 381–389 (1997). https://doi.org/10.1007/BF00881809

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00881809

Key words

Search

Navigation